上海复宏汉霖生物技术股份有限公司（02696）于2026年1月6日公布截至2025年12月31日的股份变动月报表。报告显示，公司本月未有新增发行、购回或注销股份，各类股本维持不变。
公司注册股本仍为人民币543,494,853元，包括163,428,541股于香港联交所上市的H股及380,066,312股非上市股份；两类股份数量与上月持平，均无增减。
期权与激励方面，2025年采纳的H股购股权计划当月无新行使或转让，仅有20,000份已失效。截至本月底，购股权余额为6,999,500份；同期的受限制股份单位计划也有20,000份已失效，未导致股份数量变化。
公告由公司董事Wenjie ZHANG签署。公司表示，将继续严格遵守香港联交所上市规则及相关法律法规。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.